Circulating endotrophin correlates with myocardial extracellular volume and is reduced by pirfenidone therapy, highlighting its potential as a biomarker for myocardial fibrosis in HFpEF.
Does pirfenidone reduce circulating endotrophin levels, and is endotrophin associated with myocardial ECV in patients with HFpEF?
Circulating endotrophin is a promising biomarker for myocardial fibrosis burden that is sensitive to antifibrotic therapy with pirfenidone in HFpEF.
Absolute Event Rate: 0% vs 0%
In patients with heart failure with preserved ejection fraction, treatment with pirfenidone was associated with a sustained reduction in circulating levels of endotrophin from 13 weeks. Circulating endotrophin was also independently associated with both baseline myocardial ECV and change in myocardial ECV. Endotrophin shows high potential as a circulating biomarker reflective of myocardial fibrosis burden and sensitive to change in myocardial fibrosis over time.
Black et al. (Fri,) reported a other. Circulating endotrophin correlates with myocardial extracellular volume and is reduced by pirfenidone therapy, highlighting its potential as a biomarker for myocardial fibrosis in HFpEF.